JP2024504923A5 - - Google Patents

Info

Publication number
JP2024504923A5
JP2024504923A5 JP2023541711A JP2023541711A JP2024504923A5 JP 2024504923 A5 JP2024504923 A5 JP 2024504923A5 JP 2023541711 A JP2023541711 A JP 2023541711A JP 2023541711 A JP2023541711 A JP 2023541711A JP 2024504923 A5 JP2024504923 A5 JP 2024504923A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
cdr1
cdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2023541711A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024504923A (ja
Filing date
Publication date
Priority claimed from PCT/US2021/044858 external-priority patent/WO2022032045A1/en
Application filed filed Critical
Priority claimed from PCT/US2022/012049 external-priority patent/WO2022150788A2/en
Publication of JP2024504923A publication Critical patent/JP2024504923A/ja
Publication of JP2024504923A5 publication Critical patent/JP2024504923A5/ja
Withdrawn legal-status Critical Current

Links

JP2023541711A 2021-01-11 2022-01-11 受容体ペア形成に関する組成物および方法 Withdrawn JP2024504923A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163136098P 2021-01-11 2021-01-11
US202163135884P 2021-01-11 2021-01-11
US63/136,098 2021-01-11
US63/135,884 2021-01-11
USPCT/US2021/044858 2021-08-06
PCT/US2021/044858 WO2022032045A1 (en) 2020-08-05 2021-08-06 IL10Rα/IL2Rγ SYNTHETIC CYTOKINES
PCT/US2022/012049 WO2022150788A2 (en) 2021-01-11 2022-01-11 Compositions and methods related to receptor pairing

Publications (2)

Publication Number Publication Date
JP2024504923A JP2024504923A (ja) 2024-02-02
JP2024504923A5 true JP2024504923A5 (https=) 2025-01-17

Family

ID=82358792

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023541711A Withdrawn JP2024504923A (ja) 2021-01-11 2022-01-11 受容体ペア形成に関する組成物および方法

Country Status (4)

Country Link
EP (1) EP4274616A2 (https=)
JP (1) JP2024504923A (https=)
CA (1) CA3204162A1 (https=)
WO (1) WO2022150788A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4192877A4 (en) * 2020-08-05 2024-10-16 Synthekine, Inc. SYNTHETIC IL2RB/IL2RG CYTOKINES
US12540188B2 (en) * 2020-08-05 2026-02-03 Synthekine, Inc. IL10Rα/IL2Rγ synthetic cytokines
WO2022031885A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il10ra binding molecules and methods of use
KR102773428B1 (ko) 2020-08-05 2025-02-28 신테카인, 인크. Il10 수용체 결합 분자 및 사용 방법
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4569794A (en) 1984-12-05 1986-02-11 Eli Lilly And Company Process for purifying proteins and compounds useful in such process
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5320663A (en) 1992-07-02 1994-06-14 E. I. Du Pont De Nemours And Company Method of obtaining lead and organolead from contaminated media using metal accumulating plants
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5800819A (en) 1996-01-25 1998-09-01 National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease
US6017060A (en) 1997-11-26 2000-01-25 Trw Vehicle Safety Systems Inc. Pressure relief plug
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
MXPA06014067A (es) * 2004-06-04 2007-02-15 Genentech Inc Metodo para tratar lupus.
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
EP2066336B1 (en) 2006-09-28 2012-09-19 Merck Sharp & Dohme Corp. Use of pegylated il-10 to treat cancer
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
AU2011262758B8 (en) 2010-06-11 2014-09-04 Kyowa Kirin Co., Ltd. Anti-tim-3 antibody
WO2011159877A2 (en) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
US20120201746A1 (en) * 2010-12-22 2012-08-09 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
BR112013023151A2 (pt) 2011-03-11 2020-09-15 Assistance Publique - Hôpitaux De Paris interleucina-2 para uso no tratamento de desordem auto-imune, !muno-relacionada ou inflamatória e método para determinar se um regime ou dose de il-2 tem de ser modificado
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
KR101815323B1 (ko) 2011-09-08 2018-01-05 삼성전자주식회사 복수의 무선 전력 수신기로부터 무선 전력 공급기에 신호를 송신하는 방법 및 장치
CA2868408A1 (en) 2012-03-29 2013-10-03 Aurigene Discovery Technologies Limited Immunomodulating cyclic compounds from the bc loop of human pd1
CN105658232A (zh) 2013-08-30 2016-06-08 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
CN105705489B (zh) 2013-09-04 2019-04-26 百时美施贵宝公司 用作免疫调节剂的化合物
HUE045065T2 (hu) 2014-01-31 2019-12-30 Novartis Ag TIM-3 antitest molekulák és felhasználásaik
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
US10042852B2 (en) 2014-09-29 2018-08-07 Telefonaktiebolaget Lm Ericsson (Publ) Interference and/or power reduction for multiple relay nodes using cooperative beamforming
JP2016540233A (ja) 2014-10-01 2016-12-22 オーシャン フロア ジオフィジックス インコーポレイテッドOcean Floor Geophysics Inc. 自立型水中航行機の地図作成探査のための磁気データの補償
SI3215532T1 (sl) 2014-11-06 2020-02-28 F. Hoffmann-La Roche Ag Protitelesa proti TIM3 in postopki uporabe
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
BR112017019304A2 (pt) 2015-03-10 2018-05-08 Aurigene Discovery Technologies Limited compostos de 1,2,4-oxadiazol 3-substituído e tiadiazol como imunomoduladores
KR102894264B1 (ko) 2015-03-10 2025-12-02 오리진 온콜로지 리미티드 면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물
US9708412B2 (en) * 2015-05-21 2017-07-18 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
US20160361415A1 (en) 2015-05-28 2016-12-15 Armo Biosciences, Inc. Methods of Using Interleukin-10 for Treating Diseases and Disorders
KR20180038553A (ko) 2015-08-25 2018-04-16 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
US11087249B2 (en) 2016-05-24 2021-08-10 Ciambella Ltd. Method and apparatus for triggering execution of a workflow over a network
KR20240141853A (ko) 2017-08-03 2024-09-27 신톡스, 인크. 자가면역 질환의 치료를 위한 사이토카인 접합체
US20200353050A1 (en) 2017-11-10 2020-11-12 Armo Biosciences, Inc. Compositions and methods of use of interleukin-10 in combination with immune check-point pathway inhibitors
GB201903767D0 (en) * 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers

Similar Documents

Publication Publication Date Title
JP2024504923A5 (https=)
JP7840836B2 (ja) 改善された血清アルブミン結合性免疫グロブリン可変ドメイン
US20240124584A1 (en) Igm fc and j-chain mutations that affect igm serum half-life
JP2020195399A5 (https=)
JP2009523459A5 (https=)
WO2021216468A1 (en) Human tigit specific single domain antibodies and methods of use
JP6162319B2 (ja) ヒト化抗n2抗体
RU2003126168A (ru) Терапевтические связывающие молекулы
JP2024537779A5 (https=)
CA3134224A1 (en) Composition for preventing or treating brain and nervous system disease
JP2852705B2 (ja) 自己免疫疾患の治療
US20230391863A1 (en) Bifunctional antagonists of activin and tumor necrosis factor alpha and uses thereof
CN115698077A (zh) 结合bcma的单可变结构域及抗原结合分子
KR102753603B1 (ko) 신규한 Nav1.7 모노클로날 항체
US20240343788A1 (en) Novel bifunctional multispecific antagonists capable of inhibiting multiple ligands of tgf-beta family and uses thereof
JP2024546916A5 (https=)
JP7691977B2 (ja) 抗tirc7抗原結合タンパク質
JP3773556B2 (ja) 抗アレルギー剤
AU2021365528A9 (en) Bifunctional antagonists of tumor necrosis factor-alpha and transforming growth factor-beta and uses thereof
RU2024119559A (ru) ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ ОДИНОЧНЫЕ ВАРИАБЕЛЬНЫЕ ДОМЕНЫ ИММУНОГЛОБУЛИНА, НАЦЕЛИВАЮЩИЕСЯ НА TCRαβ, CD33 и CD123
RU2025119828A (ru) Связывающие белки, связывающие pd-1×4-1bb
WO2026064762A1 (en) Anti-myostatin antibodies and methods
CN118745231A (zh) 抗ror1和cd3的双特异性抗体及其应用
US20200223927A1 (en) Methods and compositions for treating multiple sclerosis
CN118119711A (zh) 新的Nav1.7单克隆抗体